Abstract
Leukotrienes are arachidonic acid-derived lipid mediators of inflammation. The initial catalytic step in the formation of leukotrienes is catalyzed by 5-lipoxygenase (5-LOX) in conjunction with its activating partner protein FLAP. The long-awaited crystal structure of 5-LOX--reported in a recent issue of Science--should lead to novel, purpose-designed inhibitors for the treatment of asthma and for probing leukotriene involvement in cardiovascular disease and cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
